Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113608 in Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)
Latest Information Update: 31 Jan 2017
At a glance
- Drugs BI 113608 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 12 Mar 2013 New trial record